UNITED STATES
                       SECURITIES AND EXCHANGE COMMISSION
                             Washington, D.C. 20549

                                    FORM 10-Q
(Mark One)

[ X ]  QUARTERLY REPORT PURSUANT SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE
       ACT OF 1934

          For the quarterly period ended   March 31, 2008
                                           --------------
                                                or

[   ] TRANSITION REPORT PURSUANT SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE
      ACT OF 1934

           For the transition period from ______________ to _______________


         COMMISSION FILE NUMBER   000-29062


-------------------------------------------------------------------------------
                           AMERICARE HEALTH SCAN, INC.
-------------------------------------------------------------------------------
        (Exact name of registrant as specified in its charter)


       FLORIDA                               65-0714523
--------------------------        --------------------------------------------
(State or other jurisdiction of    (I.R.S. Employer Identification No.)
incorporation or organization)


     20 N.W. 181st Street
        Miami, Florida                                33169
-------------------------------------------------------------------------------
(Address of principal executive offices)           (Zip code)


                                 (305) 770-1141
-------------------------------------------------------------------------------
               (Registrant's telephone number, including area code)

                                       N/A
-------------------------------------------------------------------------------
Former name, former address and former fiscal year, if changed since last report


Indicate by check mark whether the registrant (1) has filed all reports required
to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during
the preceding 12 months (or for such shorter period that the registrant was
required to file such reports), and (2) has been subject to such filing
requirements for the past 90 days. Yes [ ] No [ X ]

Indicate by check mark whether the registrant is a large accelerated filer, an
accelerated filer, or a non-accelerated filer (as defined in Rule 12b-2 of the
Act).


       Large accelerated filer [ ]           Accelerated filer         [ ]

       Non-accelerated filer   [ ]           Smaller reporting company [x]



Indicate by check mark whether the registrant is a shell company (as defined in
Rule 12b-2 of the Exchange Act). Yes [ ] No [ X ]

Indicate the number of shares outstanding of each of the issuer's classes of
common stock, as of the latest practicable date: As of October 23, 2008 the
Issuer had 19,242,459 Shares of Common Stock outstanding.




<PAGE>


PART I - FINANCIAL INFORMATION

Item 1.  Financial Statements                                               2

           Balance Sheets as of March 31, 2008 (unaudited) and December
                31, 2007 (audited)                                          3
           Statements of Loss for cumulative amounts from development stage
             (January 1, 2005) through March 31, 2008 and for the three
              months ended March 31, 2008 and 2007 (unaudited)              4
           Statements of Cash Flows for the three months ended
              March 31, 2008 and 2007 (unaudited)                           5
           Notes to the Financial Statements (unaudited)                    6

Item 2.  Management's Discussion and Analysis or Plan Operation             7
Item 3.  Quantitative and Qualitative Disclosures About Market Risk         9
Item 4.  Controls and Procedures                                            9

PART II - OTHER INFORMATION

Item 1.   Legal Proceedings                                                10
Item 2.   Unregistered sales of equity securities and use of proceeds      10
Item 3.   Defaults upon senior securities                                  10
Item 4.   Submission of matters to a vote of security holders              10
Item 5.   Other Information                                                10
Item 6.   Exhibits and reports on Form 8-K                                 10



































                                        1
<PAGE>


                         PART I - FINANCIAL INFORMATION


ITEM 1.  FINANCIAL STATEMENTS.

The accompanying unaudited condensed financial statements of Americare Health
Scan, Inc. (the "Company") have been prepared in accordance with accounting
principles generally accepted in the United States of America for interim
financial information and with rules and regulations of the United States
Securities and Exchange Commission. Accordingly, they do not include all of the
information and footnotes required by accounting principles generally accepted
in the United States of America for complete financial statements. In the
opinion of management, all adjustments consisting of a normal and recurring
nature considered necessary for a fair presentation have been included.
Operating results for the three months ended March 31, 2008, may not necessarily
be indicative of the results that may be expected for the year ended December
31, 2008.


As used in this Quarterly Report, the terms "we," "us," "our," the "Company" and
"Americare" mean Americare Health Scan, Inc. unless otherwise indicated. All
dollar amounts in this Quarterly Report are in U.S. dollars unless otherwise
stated.



                                        2
<PAGE>


AMERICARE HEALTH SCAN, INC. (A DEVELOPMENT STAGE COMPANY)
BALANCE SHEETS
================================================================================


                                                     MARCH          DECEMBER
                                                   31, 2008         31, 2007
                                                 (UNAUDITED) (AUDITED)
                                                -------------    -------------



ASSETS

Current Assets

Cash and cash equivalents                       $         -       $      1,144
Deferred tax asset                                        -                 -
                                                ------------      ------------
   Total current assets                                   -              1,144
                                                ------------      ------------
Total assets                                    $         -       $      1,144
                                                ============      ============

LIABILITIES AND DEFICIENCY IN ASSETS

Current Liabilities

   Accounts payable and accrued expenses        $     35,709      $      34,933
   Accrued interest payable                        2,129,993          2,030,893
   Accrued officer's compensation                  2,444,000          2,392,000
   Due to shareholder                                 53,831             53,831
   Notes payable - related parties                 2,923,764          2,923,764
                                                ------------      -------------
     Total current liabilities                     7,587,297          7,435,421
                                                ------------      -------------

Deficiency in assets

   Common stock; $0.001 par value;
     50,000,000 shares authorized;
     19,242,459 shares issued and outstanding         19,242             19,242
   Additional paid-in capital                      1,662,250          1,662,250
   Accumulated deficit from development stage     (2,369,578)        (2,216,558)
   Accumulated deficit                            (6,899,211)        (6,899,211)
                                                ------------       ------------
    Total deficiency in assets                    (7,587,297)        (7,434,277)
                                                ------------       ------------
Total liabilities and deficiency in assets      $         -        $      1,144
                                                ============       ============









                             See accompanying notes.



                                        3
<PAGE>
<TABLE>
AMERICARE HEALTH SCAN, INC. (A DEVELOPMENT STAGE COMPANY)
STATEMENTS OF LOSS (UNAUDITED)
===============================================================================================================================
<CAPTION>
<S>                                                                     <C>                     <C>                  <C>

                                                                      Cumulative Amounts
                                                                       From Development
                                                                       Stage (January 1,        Three               Three
                                                                         2005) through       Months Ended        Months Ended
                                                                        March 31, 2008      March 31, 2008      March 31, 2007
-------------------------------------------------------------------   -----------------   -----------------   -----------------
REVENUE                                                               $             -     $             -     $             -
                                                                      -----------------   -----------------   -----------------

GENERAL AND ADMINISTRATIVE EXPENSES
   Auto expense                                                                   3,226                  -                   18
   Bank fees and service charges                                                 10,779                  -                   -
   Insurance                                                                     23,044                  -                   -
   Legal and professional                                                        42,545                  -                  561
   Management fees                                                               72,195                  -                5,550
   Meals and entertainment                                                        4,073                  -                   -
   Office expense                                                                 7,336                  -                  510
   Officer's compensation                                                       676,000               52,000             52,000
   Penalties and interest                                                        23,353                1,645                 50
   Postage and delivery                                                           2,060                  275                 -
   Repairs and maintenance                                                        3,730                  -                 -
   Salaries and wages                                                           199,818                  -                   -
   Taxes and licenses                                                            20,076                  -                   -
   Telephone                                                                     20,828                  -                1,805
   Travel                                                                        27,216                  -                   -
   Utilities                                                                     46,442                  -                3,171
                                                                    --------------------   ------------------   ----------------
      Total general and administrative expenses                               1,182,721               53,920             63,665
                                                                    --------------------   ------------------   ----------------
Loss before other income (expenses)                                          (1,182,721)             (53,920)           (63,665)
                                                                    --------------------   ------------------   ----------------
OTHER INCOME (EXPENSES)
   Other income                                                                  90,451                  -                6,386
   Interest expense                                                          (1,275,507)             (99,100)          (114,142)
   Other expense                                                                 (1,801)                 -                   -
                                                                    --------------------   ------------------   ----------------
        Total other expenses                                                 (1,186,857)             (99,100)          (107,756)
                                                                    --------------------   ------------------   ----------------
Loss before income taxes                                                     (2,369,578)            (153,020)          (171,421)

Provision for income taxes                                                           -                   -                   -
                                                                    --------------------   ------------------   ----------------
Net loss                                                            $        (2,369,578)   $        (153,020)   $      (171,421)
                                                                    ====================   ==================   ================

Net loss per share - basic and diluted                                                     $           (0.01)   $         (0.01)
                                                                                           ==================   ================
Weighted average number of shares
   of common stock outstanding - basic and diluted                                                19,242,459         19,242,459
                                                                                           ==================   ================
<FN>
  See accompanying notes.
</FN>
</TABLE>


                                        4
<PAGE>
<TABLE>
AMERICARE HEALTH SCAN, INC. (A DEVELOPMENT STAGE COMPANY)
STATEMENTS OF CASH FLOWS (UNAUDITED)
====================================================================================================================================
<CAPTION>
<S>                                                                                                 <C>                <C>
For the three months ended March 31,                                                              2008                 2007
---------------------------------------------------------------------------------------- --------------------- -------------------

CASH FLOWS FROM DEVELOPMENT STAGE ACTIVITIES
    Net loss                                                                                 $       (153,020)  $        (171,421)

    Change in assets and liabilities:
       Increase (Decrease)in accounts payable and accrued expenses                                        776             (78,822)
       Increase in accrued interest                                                                    99,100             114,142
       Increase in accrued officer's compensation                                                      52,000              52,000
---------------------------------------------------------------------------------------- --------------------- -------------------
    NET CASH USED IN DEVELOPMENT STAGE ACTIVITIES                                                      (1,144)            (84,101)
---------------------------------------------------------------------------------------- --------------------- -------------------

CASH FLOWS FROM FINANCING ACTIVITIES
    Net transactions from notes payable - related parties                                                 -                57,374
    Due to stockholder                                                                                    -                26,275
---------------------------------------------------------------------------------------- --------------------- -------------------
    NET CASH PROVIDED BY FINANCING ACTIVITIES                                                             -                83,649
---------------------------------------------------------------------------------------- --------------------- -------------------
NET INCREASE (DECREASE) IN CASH AND CASH EQUIVALENTS                                                   (1,144)               (452)
CASH AND CASH EQUIVALENTS, beginning of period                                                          1,144               1,220
---------------------------------------------------------------------------------------- --------------------- -------------------
CASH AND CASH EQUIVALENTS, end of period                                                     $             -    $             768
==================================================================================================================================

SUPPLEMENTAL DISCLOSURES:
Income taxes paid                                                                            $           -     $            -
Interest paid                                                                                $           -     $            -
                                                                                             ================= =====================





<FN>
                             See accompanying notes.
</FN>
</TABLE>

                                        5
<PAGE>

AMERICARE HEALTH SCAN, INC. (A DEVELOPMENT STAGE COMPANY)
NOTES TO THE FINANCIAL STATEMENTS (UNAUDITED)

1. DEVELOPMENT STAGE ACTIVITIES

         Americare Health Scan, Inc. (the "Company") was incorporated under the
         laws of the State of Florida on February 3, 1994, and is engaged in the
         business of developing technological solutions for medical, dental, and
         high tech industries, and consequently bringing the developed
         technologies to the market place. The Company has been researching
         products for development. The Company has not yet obtained necessary
         approvals to market the products it is developing. Commencing January
         1, 2005, the Company is considered to be in the development stage.

         BASIS OF PRESENTATION

         The accompanying interim financial statements have been prepared by the
         company in conformity with generally accepted accounting principles in
         the United States of America for interim financial statements. In the
         opinion of management, the accompanying interim financial statements
         contain all adjustments necessary (consisting of normal recurring
         accruals) to present fairly the financial information contained
         therein. These interim financial statements do not include all
         disclosures required by generally accepted accounting principles in the
         United States of America. The results of operation for the three months
         ended March 31, 2008, are not necessarily indicative of the results to
         be expected for the year ending December 31, 2008.

         RECLASSIFICATION

         Certain amounts in the prior year financial statements have been
         reclassified for comparative purposes to conform to the current year
         presentation. There was no material changes in classifications made to
         previously issued financial statements.

2. GOING CONCERN

         As reflected in the accompanying financial statements, the Company
         incurred net losses of $153,020 and $171,421 for the quarters ended
         March 31, 2008 and 2007, due principally to expenses incurred for
         general and administrative expenses and interest expense. To date the
         Company has not generated sufficient cash flows to sustain the
         operations. Management of the Company is developing a plan to finance
         its continuing research and development activities through the issuance
         of debt or equity securities. The ability of the Company to continue as
         a going concern is dependent on the success of the plan and the
         continued support of the Company's major shareholder. The financial
         statements do not include any adjustments that might be necessary if
         the Company is unable to continue as a going concern.

3. NET LOSS PER COMMON SHARE

         Net loss per common share has been computed (basic and dilutive) for
         all periods presented and is based on the weighted average number of
         shares outstanding during the period.

4. DUE TO RELATED PARTIES

         The Company received loans from stockholders in exchange for on-demand
         promissory notes. These notes accrued interest at a compounded rate of
         the prime rate (5.25% at March 31, 2008) plus 2% as of the last day of
         the quarter, but no less than 8% or greater than 18%. The aggregate
         principal balance of these notes at March 31, 2008 amounted to
         $2,923,764. Interest expense for the quarter ended March 31, 2008
         amounted to $99,100.


5. COMMITMENTS AND CONTINGENCIES

         The Company has an employment agreement with the President and Chief
         Executive Officer for an indefinite period of time or until there is a
         majority vote by the Board of Directors to elect a new President and
         Chief Executive Officer. The agreement calls for compensation in the
         amount of $208,000 per calendar year, which has been accrued and
         amounts to $2,444,000 and $2,236,000 at March 31, 2008 and 2007.

         The Company has not filed its 2006 or 2007 federal income tax returns.



                                        6
<PAGE>
ITEM 2.  MANAGEMENT'S DISCUSSION AND ANALYSIS OR PLAN OF OPERATION.

Cautionary Statement Regarding Forward-Looking Statements

Certain statements contained in this Quarterly Report constitute
"forward-looking statements." These statements, identified by words such as
"plan," "anticipate," "believe," "estimate," "should," "expect" and similar
expressions include our expectations and objectives regarding our future
financial position, operating results and business strategy. These statements
reflect the current views of management with respect to future events and are
subject to risks, uncertainties and other factors that may cause our actual
results, performance or achievements, or industry results, to be materially
different from those described in the forward-looking statements. Such risks and
uncertainties include those set forth under the caption "Management's Discussion
and Analysis or Plan of Operation" and elsewhere in this Quarterly Report. We
advise you to carefully review the reports and documents we file from time to
time with the Securities and Exchange Commission (the "SEC"), particularly our
Annual Reports on Form 10-K and our Current Reports on Form 8-K.

GENERAL

Americare Health Scan, Inc. is a development stage company that was incorporated
under the laws of the State of Florida on February 3, 1994. We developed the
first non-invasive, rapid, non-radioactive technology for the direct detection
of the disease process known as Active Helicobacter Pylori ("H-Pylori") for
patients with Peptic Ulcer diseases. The Ana-Sal(R) Saliva Test for H. Pylori is
simple, provides a cost-effective means for direct sampling, and requires only a
thirty second procedure for the detection of active H. Pylori infection.
Estimates suggest that almost 10 million Americans are diagnosed each year with
Peptic Ulcers. Although saliva diagnostic testing is in its infancy, the broader
diagnostic test market is highly competitive. As a result, it will be difficult
for saliva diagnostic tests to take market share from serum and urine diagnostic
tests. We believe that the market for the ANA-SAL(R) saliva based tests have a
significant growth potential. Demand for point of care and field diagnostics,
especially at border crossing points between countries, is also increasing. We
also believe that a saliva-based non-invasive method of testing will expand this
opportunity significantly.

PLAN OF OPERATION

Our ultimate objective is to build a fully integrated research and development,
manufacturing, marketing and distribution organization capable of providing the
medical diagnostic and drug delivery markets with products that offer accuracy,
efficacy, ease of use and reduced costs. In order to accomplish this objective,
we have developed the following strategy:

Provide a Broad Range of Products

We believe that a diversified product base can increase potential business
opportunities, provide a stream of new product introductions over time, and
reduce the risks associated with reliance on a single product or technology.

Focus on Large Market Opportunities

We will concentrate our development efforts on large existing markets in which
we believe there could be significant demand for our products.

                                        7
<PAGE>

Enter into Strategic Alliances

We intend to enter into strategic alliances with large medical diagnostic and
pharmaceutical companies for the marketing of our medical diagnostic products.
Since these companies have significantly greater financial, marketing and other
resources than we have, they would be able to market the our products through a
broad range of distribution channels. Our strategy with respect to the
development and commercialization of its transdermal drug delivery products is
to enter into strategic alliances with third parties that can, in some cases,
fund a portion of product development costs, participate in clinical testing,
obtain regulatory approval, and market the products. In an effort to exercise
control over the quality of our products and capture a larger portion of the
revenues, we will seek to retain manufacturing rights to products developed
under such strategic alliances.


Cash Requirements for Next Twelve Months

We anticipate that we will incur over $600,000 over the twelve months beginning
January 1, 2008 for general and administrative,including professional legal and
accounting expenses associated with our reporting obligations under the U.S.
Securities and Exchange Act of 1934 and the estimated costs of providing
products, and interest expense. Based on our cash position, we will require
additional financing to enable us to pay for our expenses. We anticipate that
additional funding will be in form of equity financing from the sale of our
common stock during the fourth quarter of 2008.

Revenue

We have incurred a net loss of $153,020 during the quarter ended March 31, 2008.
We do not anticipate earning revenues until such time as we have entered all
technologies or products for sale in the country-regionplaceUnited States. As
such, there are no costs of revenue. These previously mentioned products or
technologies have not been approved by the Food and Drug Administration ("FDA").
Except for the Saliva Collector and HIV Saliva Test, none of our technologies is
ready for sale outside of the United States either. The completion of research
and development that would be necessary to turn our technologies into working
prototypes and viable products will require a significant influx of funding. We
do not currently have the funds to undertake any research and development
efforts with regard to our technologies, and there is no assurance that we will
ever be able to obtain such funding.

Interest Expense

On-demand promissory note agreements entered into with stockholders currently
accrue compounded interest at the prime rate plus 2 %. Since January 2004, the
Company has not paid interest on these notes. Once additional equity financing
is received, management intends to repay these notes and unpaid interest.
Additional financing is anticipated in the fourth quarter of 2008.

                                        8
<PAGE>

<TABLE>

LIQUIDITY AND FINANCIAL CONDITION
<CAPTION>
<S>                                                 <C>                         <C>                    <C>

Working Capital
                                     --------------------------- ---------------------------- ---------------------------
                                                 March 31, 2008               March 31, 2007          Percentage
                                                                                                Increase / (Decrease)
                                     --------------------------- ---------------------------- ---------------------------
Current Assets                         $                    -      $                    768             (100.00) %

Current Liabilities                                  7,587,297                    6,917,369               10.01  %
                                     --------------------------- ---------------------------- ---------------------------
Working Capital  Deficiency           $             (7,587,297)     $            (6,916,601)              10.01  %
                                     =========================== ============================ ===========================

Cash Flows

                                                                 Three Months Ended March     Three Months Ended March
                                                                         31, 2008                     31, 2007
                                                                ---------------------------- ---------------------------
Cash Flows Used In Development Stage Activities                     $                (1,144)   $            (84,101)
Cash Flows Provided By Investing Activities                         $                     -    $                 -
Cash Flows Provided By Financing Activities                         $                     -    $             84,101
                                                                ---------------------------- ---------------------------
Net (Decrease) Increase In Cash During Period                       $                (1,144)   $                 -
                                                                ============================ ===========================

</TABLE>

Future Financing Requirements

We require additional financing if we are to continue as a going concern to
finance our business operations. We anticipate that any additional financing
would be through the sale of our common stock. We are presently in the process
of negotiating private placements of securities to raise working capital to
finance our operations. However, we expect to raise the additional capital that
we require to continue operations. In the event that we are unable to raise
additional financing on acceptable terms, we intend to reduce our exploration
expenditures and may implement additional actions to reduce general and
administrative expenditures. We anticipate that our working capital will
continue to decline until we receive additional funding.


Item 3.  Quantitative and Qualitative Disclosures About Market Risk


There have been no material changes in our primary risk exposures or management
of market risks from those disclosed in our Form 10-KSB for the fiscal year
ended December 31, 2007.



ITEM 4.  CONTROLS AND PROCEDURES.

Under the supervision and with the participation of our management, including
our Chief Executive Officer and Chief Financial Officer, we have evaluated the
effectiveness of our disclosure controls and procedures as required by Exchange
Act Rule 13a-15(b) as of the end of the period covered by this report. Based on
that evaluation, the Chief Executive Officer and Chief Financial Officer have
concluded that these disclosure controls and procedures are effective.

There were no changes in our internal control over financial reporting during
the quarter ended March 31, 2008, that have materially affected, or are
reasonably likely to materially affect, our internal control over financial
reporting.



                                        9
<PAGE>

                           PART II - OTHER INFORMATION


ITEM 1.  LEGAL PROCEEDINGS.

None.


ITEM 2.  UNREGISTERED SALES OF EQUITY SECURITIES AND USE OF PROCEEDS.

None.


ITEM 3.  DEFAULTS UPON SENIOR SECURITIES.

None.


ITEM 4.  SUBMISSION OF MATTERS TO A VOTE OF SECURITY HOLDERS.

None.


ITEM 5.  OTHER INFORMATION.

None.


ITEM 6.  EXHIBITS AND REPORTS ON FROM 8K.

None.




                                       10
<PAGE>

                                   SIGNATURES

In accordance with Section 13 or 15(d) of the Exchange Act, the registrant
caused this report to be signed on its behalf by the undersigned, thereunto duly
authorized.



                        / S / AMERICARE HEALTH SCAN, INC.
                        ----------------------------------
                                  (Registrant)



                          By:/s/ Dr. Joseph P. D'Angelo
                         -------------------------------
                          DR. JOSEPH P. D'ANGELO PRESIDENT AND CHIEF EXECUTIVE
                          OFFICER

Date:  October 23, 2008

In accordance with the Exchange Act, this report has been signed by the
following persons on behalf of the registrant and in the capacities and on the
dates indicated.



                          By:/s/ Dr. Joseph P. D'Angelo
                         ---------------------------
                         DR. JOSEPH P. D'ANGELO PRESIDENT AND CHIEF EXECUTIVE
                         OFFICER

Date:  October 23, 2008


                         By:/s/ Robert Cano
                         ----------------------------
                        ROBERT CANO
                        CHIEF FINANCIAL OFFICER

                                       11
<PAGE>